Song Hee-Sung, Lee Su Jin, Yoon Seok-Ho, Lee Jandee, Soh Euy-Young, An Young-Sil, Yoon Joon-Kee
Department of Nuclear Medicine, Ajou University School of Medicine, San 5, Woncheon-dong, Yeongtong-gu, Suwon, Korea.
Department of Surgery, Ajou University School of Medicine, San 5, Woncheon-dong, Yeongtong-gu, Suwon, Korea.
Nucl Med Mol Imaging. 2011 Sep;45(3):197-202. doi: 10.1007/s13139-011-0097-5. Epub 2011 Jul 26.
We investigated the clinical significance of diffuse uptake in remaining thyroid after unilateral lobectomy for thyroid cancer.
A total of 144 thyroid cancer patients who underwent (18)F-FDG PET/CT after lobectomy were enrolled in the present study. The PET/CT images were evaluated for the presence of diffuse (18)F-FDG uptake with maximum SUV (SUVmax) >2.0 in the residual thyroid and placed into one of two groups: with diffuse uptake and without diffuse uptake group. Clinical, laboratory, and PET/CT parameters in both groups were compared. Correlations between SUVmax of thyroid and available parameters were analyzed.
Forty-two of 144 patients (29.2%) had diffuse thyroid uptake (mean SUVmax: 3.2 ± 1.1). All patients with diffuse uptake and 96 (94.1%) without diffuse uptake were receiving thyroxine therapy (P = 0.09). Thyroid function tests showed that most patients were euthyroid status (78.6 vs. 85.3%, P = 0.36). TgAb levels were significantly higher in patients with diffuse uptake (338.0 ± 664.6 vs. 57.3 ± 46.4, P < 0.0001). Mean attenuation values in the diffuse uptake group were significantly lower (72.2 ± 15. vs. 97.0 ± 16.0, P < 0.0001). An inverse correlation was found between SUVmax and mean attenuation values of residual thyroid in all patients (r = -0.57, P < 0.0001) and subgroup with diffuse uptake (r = -0.31, P < 0.05).
In this study, diffuse (18)F-FDG uptake in the residual thyroid after unilateral lobectomy was a relatively frequent finding and may be associated with chronic thyroiditis. This uptake is not influenced by thyroid status or thyroxine therapy. The (18)F-FDG uptake is inversely correlated with mean attenuation value of thyroid.
我们研究了甲状腺癌单侧叶切除术后残余甲状腺弥漫性摄取的临床意义。
本研究纳入了144例甲状腺癌患者，这些患者在叶切除术后接受了（18）F-FDG PET/CT检查。对PET/CT图像进行评估，以确定残余甲状腺中是否存在最大标准摄取值（SUVmax）>2.0的弥漫性（18）F-FDG摄取，并将患者分为两组：有弥漫性摄取组和无弥漫性摄取组。比较两组的临床、实验室和PET/CT参数。分析甲状腺SUVmax与可用参数之间的相关性。
144例患者中有42例（29.2%）出现甲状腺弥漫性摄取（平均SUVmax：3.2±1.1）。所有有弥漫性摄取的患者和96例（94.1%）无弥漫性摄取的患者均接受甲状腺素治疗（P = 0.09）。甲状腺功能检查显示，大多数患者甲状腺功能正常（78.6%对85.3%，P = 0.36）。有弥漫性摄取的患者TgAb水平显著更高（338.0±664.6对57.3±46.4，P < 0.0001）。弥漫性摄取组的平均衰减值显著更低（72.2±15对97.0±16.0，P < 0.0001）。在所有患者中，残余甲状腺的SUVmax与平均衰减值呈负相关（r = -0.57，P < 0.0001），在有弥漫性摄取的亚组中也是如此（r = -0.31，P < 0.05）。
在本研究中，单侧叶切除术后残余甲状腺出现弥漫性（18）F-FDG摄取是一个相对常见的发现，可能与慢性甲状腺炎有关。这种摄取不受甲状腺状态或甲状腺素治疗的影响。（18）F-FDG摄取与甲状腺的平均衰减值呈负相关。
